Australia markets closed

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.6400-0.1400 (-3.70%)
At close: 04:00PM EDT
3.8100 +0.17 (+4.67%)
After hours: 07:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.07B
Enterprise value 445.94M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)29.54
Price/book (mrq)0.95
Enterprise value/revenue 12.46
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.36
52-week change 3-44.93%
S&P500 52-week change 326.49%
52-week high 38.0500
52-week low 33.6200
50-day moving average 34.2272
200-day moving average 34.8358

Share statistics

Avg vol (3-month) 31.39M
Avg vol (10-day) 31.35M
Shares outstanding 5294.05M
Implied shares outstanding 6294.05M
Float 8192.15M
% held by insiders 127.98%
% held by institutions 142.92%
Shares short (15 Apr 2024) 423.09M
Short ratio (15 Apr 2024) 423.23
Short % of float (15 Apr 2024) 410.22%
Short % of shares outstanding (15 Apr 2024) 47.86%
Shares short (prior month 15 Mar 2024) 423.04M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-719.61%

Management effectiveness

Return on assets (ttm)-9.79%
Return on equity (ttm)-12.27%

Income statement

Revenue (ttm)38.02M
Revenue per share (ttm)0.13
Quarterly revenue growth (yoy)-57.40%
Gross profit (ttm)N/A
EBITDA -212.81M
Net income avi to common (ttm)-146.4M
Diluted EPS (ttm)-0.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)760.59M
Total cash per share (mrq)2.6
Total debt (mrq)77.38M
Total debt/equity (mrq)6.72%
Current ratio (mrq)7.33
Book value per share (mrq)3.96

Cash flow statement

Operating cash flow (ttm)-43.88M
Levered free cash flow (ttm)-102.96M